The compliance
advantage in cannabis.
Medicexum is the regulatory and commercial partner for suppliers, importers and clinics building inside the UK's most scrutinised emerging market.
Which licences does your operation actually need?
Four questions. An indicative regulatory stack in under a minute.
The UK is the fastest growing regulated cannabis market in Europe.
Prescription volumes have grown more than tenfold since 2019 and imports doubled last year. Supply is concentrated in a handful of pharmacies, and the ACMD review is pending. Operators that treat compliance as competitive advantage will own the decade.
Items of privately prescribed unlicensed cannabis dispensed in English community pharmacies, 2025.
up 154% on 2024
NHSBSA FOI-03941, released 30 July 2026. Calendar years, England, community pharmacy dispensing.
Privately prescribed unlicensed Schedule 2 CBPM items
Source: CQC, The safer management of controlled drugs, annual updates to 10 July 2026. England and Wales, financial years. Growth of 130% then 134%. This is a different basis to the headline NHSBSA figure, so the two series are not comparable.
Imports doubled in a year
14,992kg in 2024 to 30,061kg in 2025.
Source: Prohibition Partners, UK Medical Cannabis Market Update, 24 June 2026. Canada supplied approximately 57%.
Of CBPM supplied in England came from 10 of the 25 registered pharmacies
Source: GPhC, October 2025.
UK marketing authorisations
CBPM products available
Almost everything prescribed in the UK is an unlicensed special.
Source: MHRA via Chambers, 28 May 2026, and Prohibition Partners, 24 June 2026.
Founder, Medicexum
Twenty five years of pharmaceutical quality, applied to cannabis.
Wilson's career was built in pharmaceutical quality and validation, across GSK, Sanofi, AstraZeneca, Fujifilm Diosynth and Novartis, including commissioning, qualification and remediation programmes run to MHRA and FDA expectations. That is where the standard comes from.
He went on to lead quality and operations for a team of more than two hundred, and held a Global Head of Quality role inside a FTSE 100 business. Medicexum applies that standard to a market where most operators are still learning it as they go.
- Responsible Person (GDP), Cogent Skills gold standard
- Associate, Chartered Quality Institute
- IATCA certified Lead Auditor
- BSc (Hons) Biotechnology
We don't just advise on compliance systems. We build them.
Four production compliance tools, built in house. Two are free to use.
We don't just quote the science.
We index it.
A live library of peer reviewed cannabis research, regulatory bulletins and ongoing trials, graded, tagged and updated weekly. Built for clinicians, importers and policy teams who need evidence at hand.
- Grade A135
- Grade B168
- Grade C124
- Grade D71
Latest thinking
Compliance is no longer a cost centre. It is the moat. The operators who treat MHRA, GDP and EU GMP as a strategic asset will define the UK market for the next decade.